Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)
Open Access
- 7 July 2017
- journal article
- research article
- Published by Springer Nature in Metabolomics
- Vol. 13 (8) , 98
Abstract
Everolimus selectively inhibits mammalian target of rapamycin complex 1 (mTORC1) and exerts an antineoplastic effect. Metabolic disturbance has emerged as a common and unique side effect of everolimus.Keywords
This publication has 42 references indexed in Scilit:
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from LongevityScience, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growthProceedings of the National Academy of Sciences, 2011
- Hypoxia-Inducible Factors and the Response to Hypoxic StressMolecular Cell, 2010
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1Molecular Cell, 2010
- Interdependence of AMPK and SIRT1 for Metabolic Adaptation to Fasting and Exercise in Skeletal MuscleCell Metabolism, 2010
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent mannerProceedings of the National Academy of Sciences, 2008
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004